Skip to search formSkip to main contentSkip to account menu

Xolair

National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

omalizumab
omalizumab 150 MG Injection [Xolair]omalizumab Injection [Xolair]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Omalizumab for treatment of chronic urticaria: A review of effective dose
Omalizumab (Xolair®), a humanized anti-IgE monoclonal antibody, is effective and well-tolerated in patients with chronic… 
2018
2018
Deux cas de réactions anaphylactiques après injection d’omalizumab
2017
2017
Evaluation of Xolair® (omalizumab) Therapy in Patients Treated at Örebro University Hospital 2006-2017
Evaluation of Xolair® (omalizumab) Therapy in Patients Treated at Orebro University Hospital 2006-2017 
2016
2016
Omalizumab et mastocytose : une efficacité spectaculaire après un an de recul
Review
2014
Review
2014
Therapeutic Antibody Case Study: Humanized Xolair
This review focuses on the production, mode of action, possible toxicity, current and future research of xolair as a humanised… 
Review
2013
Review
2013
Engineering approaches to develop the next generation of antibodies to respiratory targets.
Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) represent a significant health… 
Review
2012
Review
2012
Spotlight on Omalizumab in Allergic Asthma
Omalizumab (Xolair®) is a humanized monoclonal antibody used in the treatment of adolescent and adult patients with moderate to… 
2012
2012
Efficacité d’un traitement par omalizumab dans l’urticaire au froid idiopathique sévère
2011
2011
Xolair: A New Monoclonal Drug Anti-IgE Antibody for the Treatment of Allergic Asthma
Xolair is a monoclonal antibody that binds the Ce3 domain of IgEs, inducing a conforma-tional change of the immunoglobulin, a… 
2008
2008
Anti-IgE Therapie (off-label-use) bei schwerer Erdnussallergie mit rezidivierender Anaphylaxie1
Anamnese: Diagnostik: Verlauf: History: Diagnostics: Medical Course: 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)